Article Information
History
- December 20, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Leire de Campos Mata1,*,
- Janet Piñero2,*,
- Sonia Tejedor Vaquero1,
- Roser Tachó-Piñot1,
- Maria Kuksin3,
- Itziar Arrieta Aldea4,
- Natalia Rodrigo Melero5,
- Carlo Carolis5,
- Laura Furlong2,
- Andrea Cerutti1,3,6,
- Judit Villar-García4 and
- Giuliana Magri1,#
- 1Translational clinical research program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain
- 2Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Pompeu Fabra University (UPF), Barcelona, Spain
- 3Department of Medicine, Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- 4Department of Infectious Diseases, Hospital Del Mar, 08003, Barcelona, Spain
- 5Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Dr. Aiguader, 88, 08004 Barcelona
- 6Catalan Institute for Research and Advanced Studies (ICREA), 08003 Barcelona, Spain
- ↵#Correspondence to gmagri{at}imim.es (G.M.)
↵* These authors contributed equally
Posted December 20, 2020.
SARS-CoV-2-Specific Antibody Profiles Distinguish Patients with Moderate from Severe COVID-19
